SCHEMBL1187341

SCHEMBL1187341

Cc1cc(C(=O)OC(C)C)cnc1Cl

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 3/20 0.46
CA1 P00915 3/20 0.46
CA2 P00918 3/20 0.46
CA7 P43166 3/20 0.46
CA9 Q16790 3/20 0.46
CA14 Q9ULX7 3/20 0.46
P2RY12 Q9H244 1/20 0.41
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
NPC1 O15118 1/20 0.41
RAB9A P51151 1/20 0.41
ALDH1A1 P00352 3/20 0.40
L3MBTL1 Q9Y468 2/20 0.40
PDCD1 Q15116 1/20 0.39
CD274 Q9NZQ7 1/20 0.39
JMJD6 Q6NYC1 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
KDM4E B2RXH2 1/20 0.37
MAPT P10636 1/20 0.37
MAPK1 P28482 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8337219 0.85 ALDH1A1 (0.48) CA12CA1CA2CA7CA9
SCHEMBL5368175 0.84 CA12 (0.54) CA12CA1CA2CA7CA9
SCHEMBL18358192 0.83 CA12 (0.45) CA12CA1CA2CA7CA9
SCHEMBL336046 0.81 ATM (0.51) CA12CA1CA2CA7CA9
SCHEMBL30331909 0.81 ATM (0.51) CA12CA1CA2CA7CA9
SCHEMBL18940364 0.80 CA12 (0.42) CA12CA1CA2CA7CA9
SCHEMBL18940466 0.80 CA12 (0.42) CA12CA1CA2CA7CA9
SCHEMBL1425026 0.79 CA12 (0.45) CA12CA1CA2CA7CA9
SCHEMBL990850 0.79 CYP2C9 (0.53) CA12CA1CA2CA7CA9
SCHEMBL29827661 0.78 CA12 (0.48) CA12CA1CA2CA7CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8598208-B2 Pyridine derivatives as S1P1/EDG1 receptor modulators ACTELION PHARMACEUTICALS LTD. (CH) 2013-12-03 US disclosed
EP-2262799-B1 PYRIDINE COMPOUNDS ACTELION PHARMACEUTICALS LTD (CH) 2012-07-04 EP disclosed
US-20110212998-A1 PYRIDINE DERIVATIVES AS S1P1/EDG1 RECEPTOR MODULATORS ACTELION PHARMACEUTICALS LTD. (CH) 2011-09-01 US disclosed
EP-2195311-B1 PYRIDINE DERIVATIVES AS S1P1/EDG1 RECEPTOR MODULATORS ACTELION PHARMACEUTICALS LTD (CH) 2011-03-23 EP disclosed
US-20110028448-A1 PYRIDINE COMPOUNDS ACTELON PHARMACEUTICALS LTD. (CH) 2011-02-03 US disclosed
EP-2262799-A1 PYRIDINE COMPOUNDS Actelion Pharmaceuticals Ltd. (CH) 2010-12-22 EP disclosed
EP-2195311-A1 PYRIDINE DERIVATIVES AS S1P1/EDG1 RECEPTOR MODULATORS Actelion Pharmaceuticals Ltd. (CH) 2010-06-16 EP disclosed
WO-2009109906-A1 PYRIDINE COMPOUNDS ACTELION PHARMACEUTICALS LTD (CH) 2009-09-11 WO disclosed
WO-2009024905-A1 PYRIDINE DERIVATIVES AS S1P1/EDG1 RECEPTOR MODULATORS ACTELION PHARMACEUTICALS LTD (CH) 2009-02-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110028448-A1 PYRIDINE COMPOUNDS CD47, ICOS, NFATC1 CA12 4257/4885CA1 3924/4885CA2 2918/4885
US-20110212998-A1 PYRIDINE DERIVATIVES AS S1P1/EDG1 RECEPTOR MODULATORS S1PR1, S1PR3, S1PR2 CA12 4871/4885CA1 4827/4885CA2 4516/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.